Based on the results from the PAPILLON trial, the FDA has recently expanded the approval of amivantamab plus carboplatin/pemetrexed as a first-line treatment of patients with EGFR exon 20 insertion positive NSCLC, thus becoming the first approved novel treatment in this setting (https://www.cancernetwork.com/view/fda-accepts-sbla-for-amivantamab-chemo-in-egfr-advanced-metastatic-nsclc (accessed on 20 November 2023)). Here, EGFR is linked to non-small cell lung carcinoma.